Patents Examined by Raymond J. Henley, III
  • Patent number: 10888549
    Abstract: Methods for preventing or treating subjects having cancer based on the identification of pharmaceutical agents that target cancer stem cells (CSCs) have been identified. These methods include administering to the subject an effective amount of a COX2 inhibitor and an effective amount of a YAP1 inhibitor. In addition, methods of enhancing chemotherapeutic responses in cancer patients have been discovered and are described herein.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: January 12, 2021
    Assignee: The Johns Hopkins University
    Inventors: Mohammad O. Hoque, David Sidransky, Akira Oki
  • Patent number: 10888527
    Abstract: The present invention relates to highly stable drug dosage forms comprising. The invention also contemplates said highly stable drug dosage forms for the treatment of diseases where inhibition of 4-hydroxyphenylpyruvate dioxygenase 5 will result at improving the health of the patient.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: January 12, 2021
    Assignee: DIPHARMA S.A.
    Inventors: Chiara Conti, Salvatore Agostino Giammillari, Giuseppe Maccari
  • Patent number: 10883994
    Abstract: A method of identifying cancer stem cell markers in a human primary tumor is disclosed. The method comprises: (a) in vivo passaging the primary tumor; and (b) comparing a level of at least one antigen in a first population of passaged tumor cells of the primary tumor with a second population of tumor cells of the primary tumor, wherein an increase in the amount of the antigen in the first population of tumor cells as compared to the amount of the antigen in the second population of tumor cells is indicative of a cancer stem cell marker in the human primary tumor.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: January 5, 2021
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Benjamin Dekel, Orit Harari-Steinberg
  • Patent number: 10881629
    Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: January 5, 2021
    Assignee: Natural Alternatives International, Inc.
    Inventors: Roger Harris, Mark Dunnett
  • Patent number: 10881670
    Abstract: The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester while avoiding unacceptably high testosterone levels.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: January 5, 2021
    Inventors: Nachiappan Chidambaram, Satish Kumar Nachaegari, Mahesh V. Patel, Kilyoung Kim
  • Patent number: 10874653
    Abstract: The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Sen-Jam Pharmaceutical LLC
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl
  • Patent number: 10874630
    Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 29, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10874655
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10874632
    Abstract: The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: December 29, 2020
    Inventor: Steven Baranowitz
  • Patent number: 10874656
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10874657
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 10869855
    Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 22, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10869850
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: December 22, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10869854
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: December 22, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10863764
    Abstract: The invention provides a composition comprising methylphosphonic acid or a salt thereof for human consumption. The invention also provides a method for treating aging and/or improving health in a human. Methods of the invention involve providing or administering methylphosphonic acid or a salt thereof to a human in need thereof for consumption. The invention provides nutritional and pharmaceutical compositions and articles containing such compositions including, for example, a nutritional supplement, a beverage, a food substance, a prepackaged food or meal, or a nutraceutical, as well as a pharmaceutical.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: December 15, 2020
    Inventor: Gerald E. Aardsma
  • Patent number: 10864194
    Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 15, 2020
    Assignee: Clementia Pharmaceuticals Inc.
    Inventors: Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
  • Patent number: 10864185
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 15, 2020
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10864202
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: December 15, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10864187
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: December 15, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10857160
    Abstract: It relates to an oil-in-water nanoemulsion composition having a continuous aqueous phase and dispersed oil droplets, wherein the nanoemulsion comprises: (a) clobetasol; (b) one or more oil components; and (c) one or more surfactants; together with one or more pharmaceutically acceptable excipients or carriers wherein: the osmolality of the nanoemulsion is comprised from 100 mOsm/Kg to 500 mOsm/Kg; the droplet average size measured by Dynamic light scattering is comprised from 1 nm to 500 nm; the weight ratio between the oil components and the sum of the oil components and one or more surfactants is comprised from 0.001 to 0.5; the weight ratio between the oil component and clobetasol is comprised from 1:1 to 200:1; and the weight ratio between the surfactant and clobetasol is comprised from 2:1 to 200:1. It also relates to processes for its preparation, its use as a medicament, and in the prophylaxis and/or treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: December 8, 2020
    Assignee: LABORATORIOS SALVAT, S.A.
    Inventors: Javier Sanagustin Aquilue, María Del Carmen Lendínez Gris, Maria Isabel Delgado Gañán